Brief: Corvus To Announce Results From Cohort 4 Of Placebo-Controlled Phase 1 Clinical Trial
05/01/2026 15:29
Jan 5 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O: CORVUS PHARMACEUTICALS CONFIRMS PLANS TO ANNOUNCE RESULTS FROM COHORT 4 OF PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS IN JANUARY 2026 FOLLOWING ANNUAL HEALTHCARE CONFERENCE Source text: ID:nGNX7c4S6j Further company coverage: CRVS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental